IL6 and breast cancer: A second PG, syndecan-1, plays an analogue role in modulating BCSC properties by regulating IL-6/STAT3 [171,186], as well as Notch and EGFR signaling in TNBC, and it has been recently proposed as a novel CSC marker in BC leptomeningeal metastasis [187].